Petrelintide
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Roche · Phase 2 · Completed · Enrollment 221
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Treatment A: Petrelintide Dose 1 | n/r | n/r | n/r | n/r | n/r |
| Treatment B: Petrelintide Placebo Dose 1 | n/r | n/r | n/r | n/r | n/r |
| Treatment C: Petrelintide Dose 2 | n/r | n/r | n/r | n/r | n/r |
| Treatment D: Petrelintide Placebo Dose 2 | n/r | n/r | n/r | n/r | n/r |
| Treatment E: Petrelintide Dose 3 | n/r | n/r | n/r | n/r | n/r |
| Treatment F: Petrelintide Placebo Dose 3 | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.